Key Highlights
- SoundHealth introduces SONU, FDA De Novo authorized AI-enabled wearable for nasal congestion treatment.
- SONU offers a non-pharmaceutical, at-home solution for individuals 22 and older.
- $7M seed-round funding to enhance SONU’s commercialization and seek additional indications.
- Uses acoustic resonance therapy to provide personalized relief for nasal congestion.
- Prominent investors include Moai Capital, J4 Ventures, and others.
Source: Business Wire
Notable Quotes
- “SONU’s vibroacoustic therapy offers an innovative drug-free treatment option for my patients suffering from allergic and non-allergic nasal congestion. The prospect of replacing medications with a scientifically proven non-invasive therapy is truly exciting.” — Dr. Cecelia Damask, Physician at Orlando and Lake Mary ENT & Allergy
- “SONU is using the latest medical science to provide a game-changing and liberating alternative treatment for nasal congestion. Investors are increasingly looking for high-efficacy solutions to many maladies without the side effects of pharmaceutical approaches.” — Peter Moran, Board Member at SoundHealth
SoHC's Take
SoundHealth’s launch of SONU represents a significant advancement in the treatment of nasal congestion, particularly for those seeking non-pharmaceutical options. The FDA’s De Novo authorization underscores the device’s innovative approach and effectiveness. With substantial seed-round funding, SoundHealth is well-positioned to expand its market presence and explore additional therapeutic indications. This milestone, combined with the backing of reputable investors and experts, positions SONU as a promising solution for individuals suffering from nasal congestion. The integration of AI to personalize treatment further enhances its potential, making it a compelling addition to the respiratory health landscape.
